phrykt

INNOVATE Corp. (VATE): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of VATE were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling INNOVATE

From the latest filings

Overall: more buying than selling. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns VATE

50 funds and institutions reported VATE shares worth $58.8M at the end of Q2 2026, about 23% of the company. The largest holder is Whitefort Capital Management, LP with 5.4%.

Funds and institutions (13F) 23%Everyone else 77%

10 largest owners, by share of the company

Whitefort Capital Management, LP5.4%
Jefferies Financial Group Inc.5.1%
BlackRock, Inc.2.6%
Vanguard Capital Management LLC1.7%
Geode Capital Management, LLC0.9%
Arena Capital Advisors, LLC- CA0.9%
Prescott Group Capital Management, L.L.C.0.8%
Marshall Wace, LLP0.8%
Bank of America Corp0.6%
State Street Corp0.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Whitefort Capital Management, LP743,0005.45%$13.9MNo change
Jefferies Financial Group Inc.700,8025.14%$13.1MNo change
BlackRock, Inc.354,4082.60%$6.6M+289%
Vanguard Capital Management LLC228,6671.68%$4.3M+2%
Geode Capital Management, LLC128,5300.94%$2.4M+43%
Arena Capital Advisors, LLC- CA127,9340.94%$2.4MNo change
Prescott Group Capital Management, L.L.C.109,4480.80%$2MNo change
Marshall Wace, LLP108,1470.79%$2MNew
Bank of America Corp83,2390.61%$1.6M+416%
State Street Corp82,7640.61%$1.5M+73%
ARS Investment Partners, LLC61,2460.45%$1.1MNo change
Renaissance Technologies LLC56,9800.42%$1.1MNew
Northern Trust Corp42,8370.31%$800K+238%
Vanguard Portfolio Management LLC39,0690.29%$729KNew
Bridgeway Capital Management, LLC36,5000.27%$681K+46%
Vanguard Fiduciary Trust Co34,8250.26%$650K+7%
Tudor Investment Corp Et Al32,7870.24%$612KNo change
Strs Ohio21,5000.16%$401KNew
Citadel Advisors LLC19,8160.15%$370K-45%
Gabelli Funds LLC18,0000.13%$336KNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No VATE insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VATE short interest

Low short interest. 4.0% of VATE shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went up 104%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 541,213 VATE shares were sold short, 4.0% of the shares outstanding, down 2.9% from the report before. At the average daily volume of 65,245 shares, buying them all back would take about 8.3 trading days (days to cover).

Shares short, % of all shares

3.97%May 15Oct 304.79%

Days to cover

8.3May 15Oct 3010.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026541,2133.97%-3%65,2458.3
Oct 15, 2026557,3154.09%+0%59,5969.3
Sep 30, 2026555,2644.07%-7%116,8474.8
Sep 15, 2026599,9004.40%+10%84,6497.1
Aug 31, 2026545,8644.00%+11%163,6293.3
Aug 14, 2026492,9463.61%+12%1.86M1.0
Jul 31, 2026438,3063.21%-4%90,6704.8
Jul 15, 2026456,0043.34%+16%107,7964.2
Jun 30, 2026394,7792.89%+60%170,2422.3
Jun 15, 2026246,8661.81%+1%69,4353.6
May 29, 2026243,6061.79%-8%69,1123.5
May 15, 2026265,6641.95%-1%57,1744.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

INNOVATE company events

INNOVATE filed 17 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 9, 2026.

  1. Oct 9, 2026AgreementINNOVATE Corp., a Delaware corporation has entered into a supplemental indenture to the indenture, dated August 4, 2025, among the Company, certain subsidiary guarantors, and U.S. Bank Trust Company, National Association, as trustee and collateral trustee, governing the 9.500% Convertible Senior… Filing
  2. Oct 5, 2026LeadershipThe Compensation Committee of the Board of Directors of the Company designated all equity awards outstanding under the Company’s Second Amended and Restated 2014 Omnibus Equity Award Plan at the closing of the Transaction as Replacement Awards under Section 13(b) of the Plan. Filing
  3. Sep 2, 2026DealFollowing the consummation of the Merger, on September 2, 2026, HC2 was converted into a Delaware limited liability company in accordance with the Merger Agreement (as defined below), with the name HC2 Broadcasting Holdings LLC. Filing
  4. Aug 18, 2026AnnouncementThe Company issued a press release titled "MediBeacon ® Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical Technology ”. Filing
  5. Aug 10, 2026AgreementINNOVATE Corp., a Delaware corporation, entered into a Transaction Agreement by and among the Company, IES Holdings, Inc., a Delaware corporation, IES Merger Sub, Inc., a Delaware corporation and DBM Global Intermediate Holdco Inc., a Delaware corporation. Filing
  6. Aug 6, 2026ResultsReleased financial results. Filing
  7. Aug 3, 2026AgreementINNOVATE Corp., certain subsidiary guarantors, and U.S. Bank Trust Company, National Association, as trustee and collateral trustee, entered into two supplemental indentures: (i) a supplemental indenture to the Indenture, dated August 4, 2025, governing the Company’s 10.500% Senior Secured Notes… Filing
  8. Jul 8, 2026AnnouncementThe Company issued a press release titled "INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend". Filing
  9. Jun 11, 2026VoteReported shareholder vote results. Filing
  10. Jun 1, 2026AgreementHC2 Broadcasting Holdings Inc. and HC2 Broadcasting Holdco, LLC, each an indirect wholly owned subsidiary of INNOVATE Corp., a Delaware corporation, entered into an Agreement and Plan of Merger with HC2 Merger Sub, LLC, a Delaware limited liability company, and CONX Corp., a Nevada corporation… Filing
  11. May 14, 2026ResultsReleased financial results. Filing
  12. Apr 6, 2026AnnouncementThe Company issued a press release titled "INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend". Filing
  13. Mar 31, 2026AnnouncementThe Company issued a press release titled "MediBeacon ® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation”. Filing
  14. Mar 26, 2026ResultsReleased financial results. Filing
  15. Feb 10, 2026AnnouncementThe Company issued a press release titled "Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephrology (JASN)”. Filing
  16. Feb 2, 2026AnnouncementThe Company issued a press release titled "INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend". Filing
  17. Dec 16, 2025AnnouncementThe Company issued a press release titled "MediBeacon® Next Generation TGFR TM System Receives FDA Approval”. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

INNOVATE financials

Famous investors that hold VATE

3 of the 50 well-known investors we track reported holding VATE in their latest 13F filing. The largest position is Ken Griffin's, worth $488K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202665,621$488K0.0%+231%
Paul Tudor Jones · Tudor Investment CorpQ3 202632,787$244K0.0%No change
Jim Simons · Renaissance TechnologiesQ3 202616,443$122K0.0%-71%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about INNOVATE Corp. (VATE) stock

Who owns the most VATE stock?

The largest reported owner of INNOVATE Corp. (VATE) is Whitefort Capital Management, LP, with 5.4% of the company. In total, 50 funds and institutions reported holding VATE at the end of Q2 2026, together about 23% of the shares. See the largest owners.

Are VATE insiders buying or selling?

No VATE insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in VATE?

As of Oct 30, 2026, 541,213 VATE shares were sold short, 4.0% of the shares outstanding, down 2.9% from the report before. At the average daily volume of 65,245 shares, buying them all back would take about 8.3 trading days (days to cover). See the history.

Which famous investors hold VATE?

3 of the 50 well-known investors we track reported VATE in their latest 13F filing, including Ken Griffin, Paul Tudor Jones, Jim Simons. The largest position is worth $488K. See all holders.

Executive pay

INNOVATE's chief executive was paid a total of $1.8M for the year ended Dec 31, 2025, down 33% from $2.7M the year before. In the last 12 months, INNOVATE's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$1.8MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$939KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.